Novel oral anticoagulants in patients with renal insufficiency: A meta-analysis of randomized trials

Canadian Journal of Cardiology

Volumn 30, Issue 8, 2014, Pages 888-897

  Sardar, Partha ^a   Chatterjee, Saurav ^b   Herzog, Eyal ^b   Nairooz, Ramez ^c   Mukherjee, Debabrata ^a   Halperin, Jonathan L ^d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FAILURE; META ANALYSIS; MODERATE RENAL IMPAIRMENT; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; STROKE; THIOPHENES; THROMBOEMBOLISM;

EID: 84904764432     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.04.015     Document Type: Review

References (33)

1. Hart R.G., Eikelboom J.W., Ingram A.J., Herzog C.A. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012, 8:569-578.
2. Piccini J.P., Stevens S.R., Chang Y.C., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Derivation and validation of the R2CHADS2 index in the ROCKET AF and ATRIA study cohorts. Circulation 2013, 127:224-232.
3. Poulsen B.K., Grove E.L., Husted S.E. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012, 72:1739-1753.
4. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012, 367:625-635.
5. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e44-88S.
6. Genovesi S., Santoro A. Anticoagulants, renal failure and atrial fibrillation. Expert Opin Drug Saf 2013, 12:1-3.
7. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011, 57:1339-1348.
8. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012, 33:2821-2830.
9. Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013, 34:2094-2106.
10. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
11. Hohnloser S.H., Connolly S.J. Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. Eur Heart J 2011, 32:2347-2349.
12. Pengo V., Crippa L., Falanga A., et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012, 10:1979-1987.
13. Harper P., Young L., Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012, 366:864-866.
14. Wychowski M.K., Kouides P.A. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012, 46:e10.
15. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
16. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
17. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-94.
18. Higgins JP, Altman DG, Sterne JA, eds. Assessing risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at: Accessed March 10, 2014. http://www.cochrane-handbook.org.
19. Schulman S., Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005, 3:692-694.
20. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. London: EMA, 2004 [online]. Available at: Accessed September 28, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf.
21. Bauersachs R., Berkowitz S.D., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. EINSTEIN Investigators.
22. Büller H.R., Prins M.H., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297. EINSTEIN-PE Investigators.
23. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013, 368:699-708.
24. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
25. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718.
26. Hijazi Z., Hohnloser S.H., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014, 129:961-970.
27. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
28. Kubitza D., Becka M., Mueck W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712.
29. Stangier J., Rathgen K., Stähle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
30. Riley R.D., Higgins J.P., Deeks J.J. Interpretation of random effects meta-analyses. BMJ 2011, 342:d549.
31. Büller H.R., Décousus H., Grosso M.A. HOKUSAI-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369:1406-1415.
32. Giugliano R.P., Ruff C.T., Braunwald E., et al. Once daily edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
33. Connolly S.J., Eikelboom J., Dorian P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013, 34:1498-1505.